Bombesin antagonist-based radiotherapy of prostate cancer combined with WST-11 vascular targeted photodynamic therapy Journal Article
| Authors: | Kim, K.; Zhang, H.; La Rosa, S.; Jebiwott, S.; Desai, P.; Kimm, S.; Scherz, A.; O'Donoghue, J. A.; Weber, W. A.; Coleman, J. A. |
| Article Title: | Bombesin antagonist-based radiotherapy of prostate cancer combined with WST-11 vascular targeted photodynamic therapy |
| Abstract: | Purpose: DOTA-AR, a bombesin-antagonist peptide, has potential clinical application for targeted imaging and therapy in gastrin-releasing peptide receptor (GRPr)-positive malignancies when conjugated with a radioisotope such as Y-90. This therapeutic potential is limited by the fast washout of the conjugates from the target tumors. WST-11 (Weizmann STeba-11 drug; a negatively charged water-soluble palladium-bacteriochlorophyll derivative, Tookad Soluble) vascular targeted photodynamic therapy (VTP) is a local ablation approach recently approved for use in early-stage prostate cancer. It generates reactive oxygen/nitrogen species within tumor blood vessels, resulting in their instantaneous destruction followed by rapid tumor necrosis. We hypothesize that the instantaneous arrest of tumor vasculature may provide a means to trap radiopharmaceuticals within the tumor, thereby improving the efficacy of targeted radiotherapy. Experimental Design: GRPr-positive prostate cancer xenografts (PC-3 and VCaP) were treated with Y-90-DOTA-AR with or without VTP. The uptake of radioisotopes was monitored by Cherenkov luminescence imaging (CLI). The therapeutic efficacy of the combined VTP and Y-90-DOTA-AR in PC-3 xenografts was assessed. Results: CLI of Y-90-DOTA-AR demonstrated longer retention of radiotracer within the VTP-treated PC-3 xenografts compared with the non-VTP-treated ones (P < 0.05) at all time points (24-144 hours) after Y-90-DOTA-AR injection. A similar pattern of retention was observed in VCaP xenografts. When Y-90-DOTA-AR administration was combined with VTP, tumor growth delay was significantly longer than for the control or the monotherapy groups. Conclusions: Tumorvascular arrestbyVTPimproves Y-90-DOTA-AR retention in the tumor microenvironment thereby enhancing therapeutic efficacy. (C) 2017 AACR. |
| Keywords: | tumors; generation; ablation; focal therapy; peptide receptors; wst11 |
| Journal Title: | Clinical Cancer Research |
| Volume: | 23 |
| Issue: | 13 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2017-07-01 |
| Start Page: | 3343 |
| End Page: | 3351 |
| Language: | English |
| ACCESSION: | WOS:000404723400018 |
| DOI: | 10.1158/1078-0432.ccr-16-2745 |
| PROVIDER: | wos |
| PMCID: | PMC5496795 |
| PUBMED: | 28108545 |
| Notes: | Article -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work